Probiotic Therapy (BIO-THREE) Mitigates Intestinal Microbial Imbalance and Intestinal Damage Caused by Oxaliplatin
- 6 May 2021
- journal article
- research article
- Published by Springer Nature in Probiotics and Antimicrobial Proteins
- Vol. 14 (1) , 60-71
Abstract
Gastrointestinal mucositis associated with the use of chemotherapeutic drugs can seriously affect the quality of life of patients. In this study, a probiotic mixture, BIO-THREE, was used to alleviate intestinal damage caused by oxaliplatin in mice and human patients. Kunming mice were injected with 15 mg/kg of oxaliplatin twice, and BIO-THREE tablets were administered to mice for 12 days. Patients with gastric cancer undergoing oxaliplatin treatment took BIO-THREE tablets for 2 weeks. The changes in the composition of fecal microbiota both in patients and mice were analyzed using 16S rRNA high-throughput sequencing. In mice, oxaliplatin caused a drop in body weight and produced lesions in the liver and small intestines. Probiotic therapy successfully mitigated the damage caused by oxaliplatin to the intestinal tract, but it was not very effective for the liver damage and weight loss caused by oxaliplatin. The sequencing of the gut microflora indicated that oxaliplatin treatment increased the abundance of Bacteroidetes and decreased the abundance of Prevotella in mice. After taking probiotics, the feces of mice and human patients both had a higher abundance of Plovitella and a lower abundance of Bacteroides. The increase in Bacteroidetes and decrease in Prevotella in the gut community might be associated with oxaliplatin-induced intestinal damage. Probiotics appeared to be beneficial, decreasing intestinal damage by restoring the abundance of Bacteroidetes and Prevotella.Keywords
Funding Information
- Fundamental Research Funds for the Central Universities Grant (lzujbky-2017-br01)
- National Natural Science Foundation Grant (31870082)
- Lanzhou science and technology plan project (2019-4-40)
This publication has 35 references indexed in Scilit:
- Systematic review: the role of the gut microbiota in chemotherapy‐ or radiation‐induced gastrointestinal mucositis – current evidence and potential clinical applicationsAlimentary Pharmacology & Therapeutics, 2014
- Evaluation of an Oral Subchronic Exposure of Deoxynivalenol on the Composition of Human Gut Microbiota in a Model of Human Microbiota-Associated RatsPLOS ONE, 2013
- Successful bioaugmentation of an activated sludge reactor with Rhodococcus sp. YYL for efficient tetrahydrofuran degradationJournal of Hazardous Materials, 2013
- Biomarkers of chemotherapy-induced diarrhoea: a clinical study of intestinal microbiome alterations, inflammation and circulating matrix metalloproteinasesSupportive Care in Cancer, 2013
- A Guide to Enterotypes across the Human Body: Meta-Analysis of Microbial Community Structures in Human Microbiome DatasetsPLOS Computational Biology, 2013
- Optimization of an antibiotic sensitivity assay for Mycoplasma hyosynoviae and susceptibility profiles of field isolates from 1997 to 2011Veterinary Microbiology, 2012
- Changes in Human Fecal Microbiota Due to Chemotherapy Analyzed by TaqMan-PCR, 454 Sequencing and PCR-DGGE FingerprintingPLOS ONE, 2011
- Review: Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based managementTherapeutic Advances in Medical Oncology, 2009
- Bacteroides: the Good, the Bad, and the Nitty-GrittyClinical Microbiology Reviews, 2007
- Clinical effectiveness of probiotics therapy (BIO-THREE) in patients with ulcerative colitis refractory to conventional therapyScandinavian Journal of Gastroenterology, 2007